CA
NZ
UK
AU
IND
US
In 2025, several NASDAQ-listed companies have delivered high year-to-date returns. Many draw strength from AI, cloud, memory/semi-equipment, or commercial software platforms. Below are recent financial updates for two of the leading names (Palantir, Micron), visible performance rankings, and key trends to observe.
Through mid-September 2025, several Dow Jones components have significantly outperformed their peers. Performance has been shaped by a mix of macroeconomic trends—including interest rates, sector‐specific demand (for example in finance, technology, and industrials), and regulatory or trade headwinds. Below are several companies that have …
The year 2025 is shaping into a defining period for technology companies listed on the NASDAQ. Artificial intelligence, cloud computing, cybersecurity, and semiconductors remain at the forefront of revenue growth and capital allocation. With corporate earnings from the second quarter of 2025 and early …
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NASDAQ: SNY | EURONEXT: SAN) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent® (dupilumab) in the European Union for the treatment of …
TransMedics Group, Inc. (Nasdaq:TMDX), a medical technology company focused on organ transplant therapy, announced a strategic collaboration with Mercedes-Benz Group AG to introduce a fleet of purpose-built Mercedes-Benz V-Class vehicles dedicated to organ transportation across Italy. This initiative aligns with TransMedics’ plan to replicate …
Wall Street Zen downgraded shares of Pearson plc (NYSE:PSO) from a “Buy” rating to a “Hold” rating in a research note issued on Saturday. The revision comes amid recent mixed analyst coverage, with some firms maintaining more cautious positions while others have upgraded the …
Last week, the Dow rose 1.05%, the S&P 500 climbed 1.22%, and the Nasdaq Composite jumped 2.21%, with all three indexes reaching new record highs. The rally was driven by the Fed’s expected 25-basis-point rate cut—its first since December—along with signals of two more …
U.S. stocks rose Thursday, with the Dow up 0.27%, the S&P 500 gaining 0.48%, and the Nasdaq climbing 0.94%, driven by strength in technology, industrials, and communication services. Intel surged 23% after Nvidia announced a $5 billion chip partnership, lifting Nvidia 3.5%, while Palantir, …
Skye Bioscience, Inc. (Nasdaq:SKYE), a clinical-stage biotechnology company developing therapies for obesity and metabolic health disorders, presented results from its Phase 1b study of nimacimab at the European Association for the Study of Diabetes (EASD) Annual Meeting. The trial evaluated nimacimab in subjects with …
CytomX Therapeutics, Inc. (NASDAQ:CTMX), an oncology-focused biopharmaceutical company, received an upgrade from Barclays research analysts, moving its rating to "strong-buy,". This marks the latest in a series of analyst actions on the stock.
Please wait processing your request...